389 related articles for article (PubMed ID: 32067680)
1. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
[TBL] [Abstract][Full Text] [Related]
2. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Natesan D; Zhang L; Martell HJ; Jindal T; Devine P; Stohr B; Espinosa-Mendez C; Grenert J; Van Ziffle J; Joseph N; Umetsu S; Onodera C; Turski M; Chan E; Desai A; Aggarwal R; Wong A; Porten S; Chou J; Friedlander T; Fong L; Small EJ; Sweet-Cordero A; Koshkin VS
Front Oncol; 2022; 12():816706. PubMed ID: 35321431
[TBL] [Abstract][Full Text] [Related]
3. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
4. Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Lin PC; Yeh YM; Hsu HP; Chan RH; Lin BW; Chen PC; Pan CC; Hsu KF; Hsiao JR; Shan YS; Shen MR
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503126
[TBL] [Abstract][Full Text] [Related]
5. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
[TBL] [Abstract][Full Text] [Related]
6. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
[TBL] [Abstract][Full Text] [Related]
7. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
[TBL] [Abstract][Full Text] [Related]
8. Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
Chumsri S; Sokol ES; Soyano-Muller AE; Parrondo RD; Reynolds GA; Nassar A; Thompson EA
J Natl Compr Canc Netw; 2020 May; 18(5):517-521. PubMed ID: 32380464
[TBL] [Abstract][Full Text] [Related]
9. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
10. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
12. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
Das A; Tabori U; Sambira Nahum LC; Collins NB; Deyell R; Dvir R; Faure-Conter C; Hassall TE; Minturn JE; Edwards M; Brookes E; Bianchi V; Levine A; Stone SC; Sudhaman S; Sanchez Ramirez S; Ercan AB; Stengs L; Chung J; Negm L; Getz G; Maruvka YE; Ertl-Wagner B; Ohashi PS; Pugh T; Hawkins C; Bouffet E; Morgenstern DA
Clin Cancer Res; 2023 Dec; 29(23):4770-4783. PubMed ID: 37126021
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
17. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
[TBL] [Abstract][Full Text] [Related]
18. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
[TBL] [Abstract][Full Text] [Related]
19. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
Buchhalter I; Rempel E; Endris V; Allgäuer M; Neumann O; Volckmar AL; Kirchner M; Leichsenring J; Lier A; von Winterfeld M; Penzel R; Christopoulos P; Thomas M; Fröhling S; Schirmacher P; Budczies J; Stenzinger A
Int J Cancer; 2019 Feb; 144(4):848-858. PubMed ID: 30238975
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma.
Chahoud J; Gleber-Netto FO; McCormick BZ; Rao P; Lu X; Guo M; Morgan MB; Chu RA; Martinez-Ferrer M; Eterovic AK; Pickering CR; Pettaway CA
Clin Cancer Res; 2021 May; 27(9):2560-2570. PubMed ID: 33441293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
